DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20181656

A concurrent parallel study to compare the efficacy and safety of oral iron chelators, defrasirox and defriprone in patients of beta thalassaemia major

Pankaj Gupta, Mamta Gupta, Prem Nyati, Swati P. Raipurkar, Suraj Tripathi, Sharad Thora

Abstract


Background: This study was planned to evaluate all the cases of β thalassaemia major, already receiving one of the oral iron chelators for a comparison among the efficacy, safety and economy of deferasirox and deferiprone to establish the better option in an Indian scenario.

Methods: We identified two groups of patients: 38 treated with deferasirox and 35 treated with deferiprone. Laboratory parameters such as serum ferritin, creatinine, SGPT, Hb, CBC and urine were recorded at the time of inclusion and at 1, 3 and 6 months after the inclusion. The primary outcome variable was serum Ferritin level at the start and at the end of study. Serum ferritin level was carried out by microparticle enzyme linked immunoassay.

Results: Before the study, the mean hemoglobin level was 7.32±1.50mg/dL ranged from 4 to 10.8 in deferasirox group and 7.54±1.15mg/dL ranged from 5.5 to 8.8 in deferiprone group. At the time of inclusion, study population was characterized by a mean serum ferritin value of 4735.11±450.01 SE in deferasirox and 4315.97±340.75 SE in deferiprone group. After one month the mean serum ferritin increases to 4578.66±371.96 in deferasirox and 4388.82±316.16 in deferiprone group. After three month the mean serum ferritin reduces to 4295.60±377.37 in deferasirox and 3988.88±349.84 in Deferiprone group.

Conclusions: Thus, we conclude that deferasirox and deferiprone are well tolerated, have few adverse effects and almost have a comparable effect in lowering of the patient's serum ferritin level. Deferiprone is more cost effective but needs a strict control on compliance owing to requirement in three divided doses per day.


Keywords


Beta thalassaemia major, Defrasirox, Defriprone, Efficacy, Oral iron chelators, Safety

Full Text:

PDF

References


Britton RS, Leicester KL, Bacon BR. Iron toxicity and chelation therapy. Int J Hematol. 2002;76:219-28.

Thalassaemia International Federation. Iron overload. Guidelines for the Clinical Management of Thalassaemia. 2nd Ed. Nicosia, Cyprus;2007:31-63.

Schrier SL, Angelucci E. New strategies in the treatment of Thalassaemias. Annu Rev Med. 2005;56:157-71.

Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of Thalassaemia. Blood. 1997;89:739-61.

Shah D, Dubey AP, Choudhary P. Current trends in management of beta Thalassaemia. Indian Pediatrics. 1999;36:1229-39.

Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, et al. Efficacy and safety of Deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-Thalassaemia. Escalator study. Eur J Haematol. 2009;82:458-65.

Cappellini MD, Cohen A, Piga A. A phase 3 study of Deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-Thalassaemia. Blood. 2006;107(9):3455-62.

Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Séchaud R. Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients with Transfusion-Dependent Iron Overload Due to ß-Thalassemia. J Clin Pharmacol. 2003;43:565.

Cappellini MD, Bejaoui M, Agaoglu L. Prospective evaluation of patient-reported outcomes during treatment with Deferasirox or deferoxamine for iron overload in patients with beta-Thalassaemia. Clin Ther. 2007;29:909-17.

Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to Deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-76.

Piga A, Galanello R, Forni GL. Randomized phase II trial of Deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in Thalassaemia patients with transfusional iron overload. Haematologica. 2006;91:873-80.

Maggio A, D’Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, et al. Deferiprone versus deferoxamine in patients with Thalassaemia major: a randomized clinical trial. Blood Cells Mol Dis. 2002;28(2):196-208.

Pennell D, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of Deferiprone or deferoxamine in beta-Thalassaemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-44.

Cappellini M, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of Deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-Thalassaemia. Blood. 2006;107(9):3455-62.

Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, et al. Deferasirox, Deferiprone and desferrioxamine treatment in Thalassaemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging: Haematologica 2011;96(1):41-7.

Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and Effectiveness of Long-term Therapy with the Oral Iron Chelator Deferiprone. Blood. 2003;102:1583-7.

Federica P, Anna A, Laura D, Emanuele A. management of transfusional chronic iron overload: focus on deferasirox. clinical medicine: therapeutics. 2009;1:735-45.

Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agoaglu L, et al. A phase 3 study of Deferasirox (ICL670), a once-daily oral iron chelators, in patients with β-Thalassaemia. Blood. 2006;1:107(9):3455-62.

Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Echman J, Lane P, et al. Deferasirox in sickle cell investigators. a randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-8.

Taher A, El-Beshlawy A, Elalfy M. Efficacy and Safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with b-thalassaemia: the Escalator Study. Eur J Haematol. 2009;82:458-65.

Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. haematologica. 2010;95(4):557-66.

Cohen AR, Galanello R, Piga A, DiPalma A, Vullo C, Tricta F. Safety Profile of the Oral Iron Chelator Deferiprone: a Multicenter Study. Br J Haematol. 2000;108:305-12.

Piga A, Roggero S, Salussolia I, Massano D, Serra M, Longo F. Deferiprone. Ann NY Acad Sci. 2010;1202:75-8.

Olivieri NF, Brittenham GM, McLaren CE. Long-term Safety and Effectiveness of Iron-chelation Therapy with Deferiprone for Thalassemia Major. N Engl J Med. 1998;339:417-23.

ElAlfy MS, Sari TT, Lee CL, Tricta F, El-Beshlawy A: The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol. 2010;32:601-5.